Title: 2016 ACVIM Forum Research Abstract Program Document date: 2016_5_31
ID: 2y1y8jpx_263
Snippet: The results of this study did not reveal a statistically significant difference in SPEC cPL concentrations in dogs prior to administration of GC and ≥ 3 weeks after administration of supraphysiologic doses of GCs. Thus, the administration of GCs should not compromise the clinician's ability to interpret results of SPEC cPL concentrations. The role of cytokines in pancreatitis is well characterized in human medicine. However, limited information.....
Document: The results of this study did not reveal a statistically significant difference in SPEC cPL concentrations in dogs prior to administration of GC and ≥ 3 weeks after administration of supraphysiologic doses of GCs. Thus, the administration of GCs should not compromise the clinician's ability to interpret results of SPEC cPL concentrations. The role of cytokines in pancreatitis is well characterized in human medicine. However, limited information is available about their role in dogs with pancreatitis. The aim of this study was to describe serum concentrations of interleukin (IL) -2, IL-6, IL-8, and tumor necrosis factor-alpha (TNF-a) in dogs with increased serum concentrations of pancreatic lipase immunoreactivity (cPLI; as measured as Spec cPL Ò ).
Search related documents:
Co phrase search for related documents- cPLI pancreatic lipase immunoreactivity and pancreatic lipase immunoreactivity: 1, 2, 3, 4, 5, 6
- cPLI pancreatic lipase immunoreactivity and serum concentration: 1, 2, 3
- cPLI pancreatic lipase immunoreactivity and SPEC cPL: 1, 2, 3
- cPLI pancreatic lipase immunoreactivity and study aim: 1, 2
- factor alpha and human medicine: 1
- factor alpha and serum concentration: 1, 2, 3, 4, 5
- factor alpha and statistically significant difference: 1, 2
- factor alpha and study aim: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- factor alpha and tumor necrosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76
- factor alpha and tumor necrosis factor alpha: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76
- GC administration and GCs administration: 1, 2
- GC administration and serum concentration: 1
- GC administration and SPEC cPL: 1, 2, 3
- GC administration and SPEC cPL concentration: 1
- GC administration and statistically significant difference: 1
- GC administration and study aim: 1, 2
Co phrase search for related documents, hyperlinks ordered by date